Lung Cancer
Conditions
Keywords
Lung cancer, Chinese, surgeries, adjuvant therapies
Brief summary
The study was designed to evaluate effectiveness of the surgeries and adjuvant therapies after surgeries in the patients with lung malignant tumors
Detailed description
The trial is a multi-centre real-world non-interventional observational study to evaluate effectiveness of the surgeries and adjuvant therapies after surgeries in the patients with lung malignant tumors via a retrospectively review method on the study data on patient demographic/tumor biological characteristics and clinical treatments.
Interventions
PROCEDURESurgeries
Surgeries or surgeries plus adjuvant therapies
Sponsors
LinkDoc Technology (Beijing) Co. Ltd.
West China Hospital
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age \>= 18 years old; * Pathologically diagnosed lung malignant tumors after surgeries; * Patients with lung surgeries; * Patients with complete medical health records and follow-up visit information (at least one follow-up visit);
Exclusion criteria
* Patients who were not performed with surgeries; * Pathologically diagnosed patients with benign diseases after surgeries;
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Demographic characteristics of the patients with lung malignant tumors who received surgeries | 2014 - 2017 | Demographic characteristics of the patients with lung malignant tumors who received surgeries of thoracotomy, video-assistant thoracic surgery or robotic thoracic surgery as measured by: * Age * Gender * Payment types * Insurance types * Smoking history * Complications and symptoms of complications * Respiratory functions * Type of diagnoses |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Location of tumors and tumor sizes | 2014 - 2017 | Location of tumors and tumor sizes |
| Tumor clinical/pathological staging | 2014 - 2017 | Tumor clinical/pathological staging |
| Type of biomarkers | 2014 - 2017 | Type of biomarkers |
Other
| Measure | Time frame | Description |
|---|---|---|
| Impact factors of patient survival in patients with tumor size =<2 cm who received surgeries as measured by duration and modes of surgeries | 2014 - 2017 | Impact factors of patient survival in patients with tumor size =\<2 cm who received surgeries as measured by duration and modes of surgeries |
| Impact factors of patient survival in patients with tumor size =<2 cm who received surgeries as measured by type of insurances | 2014 - 2017 | Impact factors of patient survival in patients with tumor size =\<2 cm who received surgeries as measured by type of insurances |
| Impact factors of patient survivals in the patients with N2 lung cancer with surgeries or surgeries plus adjuvant therapies | 2014 - 2017 | Impact factors of patient survivals in the patients with N2 lung cancer who received surgeries or surgeries plus adjuvant therapies |
| Overall survival in the patients with N2 lung cancer with surgeries or surgeries plus adjuvant therapies | 2014 - 2017 | Overall survival in the patients with N2 lung cancer who received surgeries or surgeries plus adjuvant therapies |
| Impact factors of patient survivals in the patients with small lung cancer with surgeries or surgeries plus adjuvant therapies | 2014 - 2017 | Impact factors of patient survivals in the patients with small lung cancer who received surgeries or surgeries plus adjuvant therapies |
| Overall survival in the patients with tumor size =< 2cm who received surgeries | 2014 - 2017 | Overall survival in the patients with tumor size =\< 2cm who received surgeries |
| Demographic characteristics of the patients with non-small cell lung cancer who were treated with chemotherapies, tyrosine kinase inhibitors, and other adjuvant therapies or were not treated with adjuvant therapies | 2014 - 2017 | Demographic characteristics of the patients with non-small cell lung cancer who were treated with chemotherapies, tyrosine kinase inhibitors, and other adjuvant therapies or were not treated with adjuvant therapies as measured by: * Age * Gender * Payment types * Insurance types * Smoking history * Complications and symptoms of complications * Respiratory functions * Type of diagnoses |
| Tumor clinical/pathological types | 2014 - 2017 | Tumor clinical/pathological types |
| Type of EGFR | 2014 - 2017 | Type of EGFR |
| ECOG scores | 2014 - 2017 | ECOG scores |
| 1-year and 3-year overall survivals | 2014 - 2017 | 1-year and 3-year overall survivals |
| Overall survival in the patients with small lung cancer with surgeries or surgeries plus adjuvant therapies | 2014 - 2017 | Overall survival in the patients with small lung cancer who received surgeries or surgeries plus adjuvant therapies |
| Differences in overall survivals of the patients with surgeries | 2014 - 2017 | Differences in perioperative overall survivals and overall survivals of the patients who received surgeries of thoracotomy, video-assistant thoracic surgery or robotic thoracic surgery |
| Impact factors of patient survival in patients with tumor size =<2 cm who received surgeries as measured by tumor clinical/pathological staging | 2014 - 2017 | Impact factors of patient survival in patients with tumor size =\<2 cm who received surgeries as measured by tumor clinical/pathological staging |
| Impact factors of patient survival in patients with tumor size =<2 cm who received surgeries as measured by location of tumors and tumor sizes | 2014 - 2017 | Impact factors of patient survival in patients with tumor size =\<2 cm who received surgeries as measured by location of tumors and tumor sizes |
Countries
China
Outcome results
None listed